Cardiovascular Disease (CVD) Phenotyping Core

心血管疾病 (CVD) 表型核心

基本信息

  • 批准号:
    10333815
  • 负责人:
  • 金额:
    $ 41.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-15 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY / ABSTRACT: Cardiovascular Disease (CVD) Phenotyping Core The Cardiovascular Disease (CVD) Phenotyping Core will be responsible for advanced subclinical and clinical CVD phenotyping of all participants enrolled in the Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS cohort (Precision-CARRS) program project grant (PPG). Responsibilities include providing coordination, expertise, and standardization of all elements related to the proposed phenotyping. The overarching goal of the Core is to obtain the highest quality of CVD subclinical and clinical phenotyping in this cohort and further train existing teams and standardize protocols for (a) novel advanced CVD phenotyping in the field, (b) cardiovascular imaging in central facilities, (c) centralized interpretation of all tests, (d) adjudication of subclinical and clinical CVD events and mortality, (e) blood and urine testing and laboratory services, together with quality assurance and quality control. The CVD Phenotyping Core will be based in Delhi, India and will consolidate and augment existing infrastructure and expertise and leverage a decade of collaborative experience between Emory and India’s leading health research institutions. Specific Aim 1 is to formulate and implement plans for accurate and reproducible phenotyping of sub-clinical CVD that includes measures of (i) functional vascular disease assessed as pulse wave velocity and augmentation index that reflect arterial stiffness; (ii) coronary artery calcium, a reflection of subclinical coronary atherosclerosis; (iii) carotid intima-media thickness and plaque; (iv) hepatic steatosis; and (v) sub-clinical myocardial dysfunction measured as left ventricular systolic or diastolic dysfunction using cardiac echo. Aim 2 will implement plans to standardize adjudication of prevalent and incident clinical CVD events to include atherosclerotic events and occurrence of heart failure. Atherosclerotic events will include incident cardiovascular death, myocardial infarction, and stroke or transient ischemic attacks. Secondary outcomes include diagnosis of angina or coronary or peripheral arterial disease, and revascularization. Heart failure occurrences will include diagnosis of symptomatic Stage C or D heart failure. In Aim 3, we will formulate and implement laboratory sample collection and analysis for all biomarkers analyses, to include traditional risk factors, advanced lipid and metabolic measures, and circulating proteins that reflect activation of pathophysiologic processes associated with CVD. The Core will work in close coordination with the Administrative and Field Coordination Core which will administer the field logistics. Acquired data will be transferred to the Data Management and Analysis Core, and provide curated CVD phenotyping data to all 4 PPG projects.
项目摘要/摘要:心血管疾病(CVD)表型研究中心

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARSHED A QUYYUMI其他文献

ARSHED A QUYYUMI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARSHED A QUYYUMI', 18)}}的其他基金

Prevalence, Incidence, and Predictors of Subclinical and Clinical Vascular and Myocardial Disease: Pathophysiologic Pathways
亚临床和临床血管和心肌疾病的患病率、发病率和预测因子:病理生理学途径
  • 批准号:
    10333816
  • 财政年份:
    2022
  • 资助金额:
    $ 41.13万
  • 项目类别:
Prevalence, Incidence, and Predictors of Subclinical and Clinical Vascular and Myocardial Disease: Pathophysiologic Pathways
亚临床和临床血管和心肌疾病的患病率、发病率和预测因子:病理生理学途径
  • 批准号:
    10622456
  • 财政年份:
    2022
  • 资助金额:
    $ 41.13万
  • 项目类别:
Cardiovascular Project 3
心血管项目3
  • 批准号:
    10459330
  • 财政年份:
    2018
  • 资助金额:
    $ 41.13万
  • 项目类别:
Cardiovascular Project 3
心血管项目3
  • 批准号:
    10231032
  • 财政年份:
    2018
  • 资助金额:
    $ 41.13万
  • 项目类别:
Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial Disease
粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 在外周动脉疾病中的应用
  • 批准号:
    9765377
  • 财政年份:
    2017
  • 资助金额:
    $ 41.13万
  • 项目类别:
Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial Disease
粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 在外周动脉疾病中的应用
  • 批准号:
    10250085
  • 财政年份:
    2017
  • 资助金额:
    $ 41.13万
  • 项目类别:
Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial Disease
粒细胞-巨噬细胞集落刺激因子 (GM-CSF) 在外周动脉疾病中的应用
  • 批准号:
    9385242
  • 财政年份:
    2017
  • 资助金额:
    $ 41.13万
  • 项目类别:
Mental Stress Ischemia: Prognosis and Genetic Influences
精神应激缺血:预后和遗传影响
  • 批准号:
    8318063
  • 财政年份:
    2010
  • 资助金额:
    $ 41.13万
  • 项目类别:
Mental Stress Ischemia: Prognosis and Genetic Influences
精神应激缺血:预后和遗传影响
  • 批准号:
    8136655
  • 财政年份:
    2010
  • 资助金额:
    $ 41.13万
  • 项目类别:
Mental Stress Ischemia: Prognosis and Genetic Influences
精神应激缺血:预后和遗传影响
  • 批准号:
    8588795
  • 财政年份:
    2010
  • 资助金额:
    $ 41.13万
  • 项目类别:

相似海外基金

CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
  • 批准号:
    2339759
  • 财政年份:
    2024
  • 资助金额:
    $ 41.13万
  • 项目类别:
    Continuing Grant
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
  • 批准号:
    2320160
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
    Standard Grant
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
  • 批准号:
    23H02481
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
  • 批准号:
    479334
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
    Operating Grants
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
  • 批准号:
    10655891
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
  • 批准号:
    10716621
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
  • 批准号:
    10604822
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
  • 批准号:
    10621634
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
Examination of risk assessment and biochemical assessment of fracture development focusing on the body composition of patients with rheumatoid arthritis
关注类风湿性关节炎患者身体成分的骨折发生风险评估和生化评估检查
  • 批准号:
    22KJ2600
  • 财政年份:
    2023
  • 资助金额:
    $ 41.13万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了